Bernard J. Zovighian - 12 Feb 2026 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CEO, Director
Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
12 Feb 2026
Net transactions value
-$217,584
Form type
4
Filing time
13 Feb 2026, 17:37:29 UTC
Previous filing
10 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zovighian Bernard J CEO, Director ONE EDWARDS WAY, IRVINE Linda J. Park, Attorney-in-Fact 13 Feb 2026 0001665141

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $1,502,157 +25,350 +31% $59.26 106,326 12 Feb 2026 Direct
transaction EW Common Stock Sale $195,290 -2,532 -2.4% $77.13 103,794 12 Feb 2026 Direct F1
transaction EW Common Stock Sale $1,524,451 -19,898 -19% $76.61 83,896 12 Feb 2026 Direct F2
transaction EW Common Stock Gift $0 -2,920 -3.5% $0.000000 80,976 13 Feb 2026 Direct
transaction EW Common Stock Gift $0 +2,920 +34% $0.000000 11,517 13 Feb 2026 By Trust
holding EW Common Stock 3,656 12 Feb 2026 401(k) F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -25,350 -100% $0.000000 0 12 Feb 2026 Common Stock 25,350 $59.26 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $77.080 to $77.225 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed in multiple trades at prices ranging from $76.080 to $77.075 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.
F4 These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.